Mubadala Capital has recently announced a significant investment of $200 million in Tenvie Therapeutics on January 9, 2025.
Tenvie, which Tony Estrada started, is focused on developing new treatments for diseases that affect the brain and nervous system, which can profoundly impact people’s lives.
Read also: HealthTech Hub Africa launches 2025 program for African health startups
A new hope for patients
Tony Estrada, the founder and chief scientist of Tenvie, expressed his vision by saying, “Tenvie was founded to fundamentally alter the treatment paradigm for neurological diseases and profoundly impact the lives of patients, their families, and caregivers.”
This means that Tenvie aims to change how we approach the treatment of these complex illnesses, making it possible to improve the quality of life for those affected.
The company is working on innovative therapies that target inflammation and restore brain function, which could lead to better outcomes for patients suffering from conditions like Alzheimer’s disease and Parkinson’s disease.
Support from Mubadala Capital
Mubadala Capital’s investment highlights its commitment to supporting groundbreaking healthcare innovations. Alaa Halawa, who leads Mubadala’s healthcare investments, remarked, “Tenvie’s approach demonstrates a commitment to addressing unmet needs in neurology.”
This funding will enable Tenvie to expand its research and development efforts significantly. With a strong lineup of potential treatments already in the pipeline, Tenvie is well-positioned to make a meaningful difference in biotechnology and help many individuals struggling with neurological disorders.
Read also: Compass Global’s initiative bridges Africa’s trade gaps, focuses on youth and women entrepreneurs
About Tenvie Therapeutics
Tenvie Therapeutics is a biotechnology company founded to improve patients’ lives with neurological, cardiometabolic, and ophthalmic diseases.
The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics.
Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.
